Replies to post #151338 on Biotech Values

[mcbio]

Dew, I don't know if you are an institutional or private investor in MNTA, but help me rationalize how you can be a fan of MNTA at a 52 week low, aka:

finance.yahoo.com/q/bc?s=MNTA+Basic+Chart&t=1y

What am I missing? Inefficient market theory at its best?

If you think that MNTA/BAX will succeed in developing interchangeable biologics of any of the large biologics they are likely targeting, I don't think it's that hard at all to envision MNTA shares likely being cheap at current valuation. This development is still likely a few years away, though, so I'm on the sidelines for now.

[DewDiligence]

Would you rather buy at a higher price??

[jmkobers]

You aren't missing anything. For the GREAT majority of the last 5 years, MNTA has been a horrible investment. Lovenox approval came on July 23rd, 2010. Prior to that, it languished for several years between 12-15 pps.

After approval, it popped BRIEFLY to 25. Dew pumped it all the way down from the top to where it is now(22 is a gift, 19 is a gift, 17 is a gift, ect). Prior to approval, he pumped that it could go to as high as 80 pps. His latest pump was a possible buyout based on a lack of 10b5-1 activity, which of course, turned out to be nothing.

Overall MNTA has potential but the risks have always outweighed any possible upside. Most who have chased a gain with MNTA have been burned, and burned badly. For any new investor, it should be viewed as a purely speculative investment.

If you do choose to invest in MNTA, my advice is to do your homework and Do NOT read RMF. Should you go all in on MNTA good luck and god bless. If history is any guide, you will certainly need it.